Research Analysts Set Expectations for TSE:FRX Q2 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Investment analysts at Wedbush increased their Q2 2026 earnings per share estimates for Fennec Pharmaceuticals in a report released on Friday, November 14th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn $0.55 per share for the quarter, up from their previous estimate of $0.52. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share.

Fennec Pharmaceuticals Stock Performance

Shares of FRX stock opened at C$11.15 on Monday. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. Fennec Pharmaceuticals has a one year low of C$5.65 and a one year high of C$13.83. The business’s 50 day simple moving average is C$12.14 and its 200 day simple moving average is C$11.52. The stock has a market capitalization of C$310.33 million, a PE ratio of -24.78 and a beta of 2.53.

Insider Buying and Selling

In other Fennec Pharmaceuticals news, insider Southpoint Capital Advisors Lp sold 20,609 shares of the company’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of C$12.89, for a total transaction of C$265,650.01. Following the sale, the insider owned 4,010,100 shares of the company’s stock, valued at approximately C$51,690,189. This represents a 0.51% decrease in their ownership of the stock. Insiders have sold a total of 68,889 shares of company stock worth $900,406 over the last quarter. Corporate insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.